Jump to main content
Jump to site search


Artificial chimeric exosomes for anti-phagocytosis and targeted cancer therapy

Author affiliations

Abstract

Development of exosome-based delivery systems is still facing some formidable challenges, including the lack of standardized isolation and purification methods, non-large-scale production and low drug-loading efficiency. Inspired by biomimetic technologies, we turned to the design of artificial chimeric exosomes (ACEs) constructed by integrating cell membrane proteins from multiple cell types into synthetic phospholipid bilayers. For benchmarking, hybrid membrane proteins derived from red blood cells (RBCs) and MCF-7 cancer cells were selected as models. The resulting ACEs were engineered much like “Emperor Qin's Terra-Cotta Warriors”, simultaneously equipped with armor (anti-phagocytosis capability from RBCs) and dagger-axes (homologous targeting ability from cancer cells). ACEs demonstrated higher tumor accumulation, lower interception and better antitumor therapeutic effect than plain liposomes in vivo, alongside large-scale standardized preparation, stable structure, high drug-loading capacity and custom-tailored functionality, highlighting the suitability of ACEs as promising alternatives of exosomes in clinical applications.

Graphical abstract: Artificial chimeric exosomes for anti-phagocytosis and targeted cancer therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 20 Jul 2018, accepted on 23 Nov 2018 and first published on 27 Nov 2018


Article type: Edge Article
DOI: 10.1039/C8SC03224F
Citation: Chem. Sci., 2019, Advance Article
  • Open access: Creative Commons BY-NC license
  •   Request permissions

    Artificial chimeric exosomes for anti-phagocytosis and targeted cancer therapy

    K. Zhang, Y. Wang, J. Sun, J. Zhou, C. Xing, G. Huang, J. Li and H. Yang, Chem. Sci., 2019, Advance Article , DOI: 10.1039/C8SC03224F

    This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

    Reproduced material should be attributed as follows:

    • For reproduction of material from NJC:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
    • For reproduction of material from PCCP:
      [Original citation] - Published by the PCCP Owner Societies.
    • For reproduction of material from PPS:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
    • For reproduction of material from all other RSC journals:
      [Original citation] - Published by The Royal Society of Chemistry.

    Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.

Search articles by author

Spotlight

Advertisements